Not Just A Tweak: UK Review Seeks Sea Change In Drug Development
This article was originally published in Scrip
Executive Summary
The UK government's Accelerated Access Review is planning to bring big and meaningful changes to the way drugs are developed and brought to UK patients and is not just a tweak to the system. So says, Dr Stuart Dollow, chief executive and founder of Vermilion Life Sciences, who is helping to lead the review.
You may also be interested in...
Denmark Introduces Early Dialogue With Procurement Agency For Expensive Medicines
Earlier dialogues would mean faster access to new medicines.
UK Government Reveals New Statutory Pricing Scheme
The scheme still includes high rebate rates, but a controversial life cycle adjustment mechanism has been dropped.
Premature Filings Add To EU Regulatory Resource Challenge
The pharmaceutical legislation overhaul offers some solutions to the problem of immature applications.